{
    "root": "311a8d76-795a-3057-e063-6394a90a9a37",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metoprolol Succinate",
    "value": "20250324",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "METOPROLOL SUCCINATE",
            "code": "TH25PD4CCB"
        }
    ],
    "indications": "Metoprolol succinate extended-release tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure. ( 1.3 )",
    "contraindications": "Administer once daily. Titrate at weekly or longer intervals as needed and tolerated. ( 2 ) Hypertension: Starting dose is 25 to 100 mg. ( 2.1 ) Angina Pectoris: Starting dose is 100 mg. ( 2.2 ) Heart Failure: Starting dose is 12.5 or 25 mg. ( 2.3 ) Switching from immediate-release metoprolol to metoprolol succinate extended-release tablets: use the same total daily dose of metoprolol succinate extended-release tablets. ( 2 )",
    "warningsAndPrecautions": "Metoprolol Succinate Extended-Release Tablets, USP are available containing 23.75 mg, 47.5 mg or 95 mg of metoprolol succinate, USP equivalent to 25 mg, 50 mg or 100 mg of metoprolol tartrate, USP, respectively.\n                  The 25 mg tablets are white to off-white, film-coated, round, scored tablets debossed with\n \n  Mabove the break line on one side of the tablet and\n \n  MT1on the other side. They are available as follows:\n\n \n                  NDC 51079-169-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).\n                  The 50 mg tablets are white to off-white, film-coated, oval, scored tablets debossed with\n \n  Mon one side of the break line on one side of the tablet and\n \n  MT2on the other side. They are available as follows:\n\n \n                  NDC 51079-170-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).\n                  The 100 mg tablets are white to off-white, film-coated, oval, scored tablets debossed with\n \n  Mon one side of the break line on one side of the tablet and\n \n  MT3on the other side. They are available as follows:\n\n \n                  NDC 51079-171-03 – Unit dose blister packages of 30 (5 cards of 6 tablets each).\n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]",
    "adverseReactions": "Metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product."
}